Aobo Capital
奥博资本
Aobo Capital — referred to in Chinese sources as 奥博资本 (OrbiMed) — is an international healthcare-focused investment firm that has led or co-led several major biotech funding rounds in China . In August 2025 it led a $131 million Pre-IPO round for Minghui Pharma alongside Qiming Venture Partners , and in March 2026 it led a Series C round of over 500 million RMB for QLT Biotherapeutics, with 5Y Capital among the co-investors . The firm also appeared as an investor in the 2021 D-round of AI drug-discovery company XtalPi, which was reported at a roughly 13 billion RMB valuation .
AI-generated — may contain errors, please verify.
Coverage
5Y News | QLT Biotherapeutics Raises Over 500 Million RMB in Series C Funding
Zhitai Biotech Closes Over 500 Million Yuan Series C Round to Accelerate Core Clinical Pipeline Development
五源资本·5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
五源资本·The Gambler's Mirage in a Downturn: When a Fund Goes All-In on a Single Company
In the investment industry, it's as ubiquitous as air. When markets plunge, it also faces the greatest risk.
暗涌Waves·
